The incidence of esophageal adenocarcinomas (EAC) has increased at an alarming rate (>400%) in the last few decades far exceeding any other cancer type in the United States, while the prognosis has remained poor (1). Most EACs are initiated by replacement of normal squamous epithelium with metaplastic mucosa known as Barrett's esophagus (BE), which subsequently progress through a dysplastic stage into invasive carcinomas (2). Although BE-affected individuals carry a 30-125 fold greater risk of developing EAC when compared to an age-matched population (3), the estimated rate of cancer progression among BE individuals is only 1 per 200 patient-years (2). This makes it difficult to identify BE patients who are at an increased risk for cancer development, and is one of the major clinical challenges in this disease. Endoscopy-based surveillance in BE patients has shown only a minimal impact in reducing cancer mortality, and is certainly not cost-effective (2). Though histology based evaluation for high-grade dysplasia (HGD) is currently used for assessing cancer risk in patients with BE, the approach is not optimal owing both to the marked inter-observer variability in interpreting dysplasia (4), and to the highly variable rates of progression to EAC (16-50% over 7 years) among HGD cases (2). Therefore, identification of novel biomarkers that reliably aid in risk stratification in BE would allow for the development of more rational surveillance strategies aimed at early cancer detection, in addition to providing a novel class of therapeutic targets for this deadly disease. Moreover, it will additionally help in curtailing health care costs by refining current screening and surveillance programs. Accordingly, the primary objective of this proposal is to identify RNA-based biomarkers associated with the risk of malignant progression in BE.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
United States
Zip Code
Chan, M Q; Blum, A E; Chandar, A K et al. (2018) Association of sporadic and familial Barrett's esophagus with breast cancer. Dis Esophagus 31:
Yu, Ming; Maden, Sean K; Stachler, Matthew et al. (2018) Subtypes of Barrett's oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis. Gut :
Berger, Nathan A (2018) New light on the pancreatic cyst conundrum. Transl Cancer Res 7:S545-S548
Berger, Nathan A (2018) Young Adult Cancer: Influence of the Obesity Pandemic. Obesity (Silver Spring) 26:641-650
Moinova, Helen R; LaFramboise, Thomas; Lutterbaugh, James D et al. (2018) Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus. Sci Transl Med 10:
Stachler, Matthew D; Camarda, Nicholas D; Deitrick, Christopher et al. (2018) Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma. Gastroenterology 155:156-167
Berger, Nathan A; Scacheri, Peter C (2018) Targeting Epigenetics to Prevent Obesity Promoted Cancers. Cancer Prev Res (Phila) 11:125-128
Codipilly, Don Chamil; Chandar, Apoorva Krishna; Singh, Siddharth et al. (2018) The Effect of Endoscopic Surveillance in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis. Gastroenterology 154:2068-2086.e5
Evans, Daniel R; Venkitachalam, Srividya; Revoredo, Leslie et al. (2018) Evidence for GALNT12 as a moderate penetrance gene for colorectal cancer. Hum Mutat 39:1092-1101
Venkitachalam, Srividya; Guda, Kishore (2017) Altered glycosyltransferases in colorectal cancer. Expert Rev Gastroenterol Hepatol 11:5-7

Showing the most recent 10 out of 69 publications